US 12,458,622 B2
Methods of treatment of coronavirus-induced inflammation conditions
David R. Elmaleh, Newton, MA (US); Ana Griciuc, Arlington, MA (US); Ghazaleh Sadri-Vakili, Watertown, MA (US); Sabrina Paganoni, Boston, MA (US); and Rudolph E. Tanzi, Milton, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Appl. No. 17/917,022
Filed by The General Hospital Corporation, Boston, MA (US)
PCT Filed Apr. 5, 2021, PCT No. PCT/US2021/025746
§ 371(c)(1), (2) Date Oct. 5, 2022,
PCT Pub. No. WO2021/207060, PCT Pub. Date Oct. 14, 2021.
Claims priority of provisional application 63/005,720, filed on Apr. 6, 2020.
Prior Publication US 2023/0149345 A1, May 18, 2023
Int. Cl. A61K 31/353 (2006.01); A61K 31/352 (2006.01); A61K 45/06 (2006.01); A61P 11/00 (2006.01); A61P 29/00 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/353 (2013.01) [A61K 31/352 (2013.01); A61K 45/06 (2013.01); A61P 11/00 (2018.01); A61P 29/00 (2018.01); A61P 31/14 (2018.01)] 25 Claims
OG exemplary drawing
 
1. A method of treating one or more inflammation condition induced by a coronavirus infection, comprising administering a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises a pharmaceutically acceptable excipient and a compound having the following chemical structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; and
wherein the one or more inflammation condition is selected from acute respiratory distress syndrome (ARDS), pneumonia, myocarditis, haemophagocytic lymphohistiocytosis (sHLH), kidney failure, septic shock, and sepsis.